Current issue
Archive
About the Journal
About us
Aims and Scope
Indexing and Abstracting
Editorial Office
Open Access Policy
Publication Ethics
Contact
For Authors
Editorial Policy
Peer Review Policy
Manuscript Preparation Guidelines
Copyright & Licensing
Publication Fees
Fast-Track Paper Publication Option
Conflict Interest Guidance
Submit an Article
Special Issues
News & Editorials
“Fake,” “Predatory,” and “Pseudo” Journals: Charlatans Threatening Trust in Science
Shifting the Journal submission-review system to the Editorial System Manuscript December 27, 2017.
ORIGINAL ARTICLE
The primary hyperparathyroidism and its complications: Substantiation of funding volume for hospital pharmacotherapy
1
Department of Organization and Economics of Pharmacy, I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, RUSSIA
2
Department of Pharmacy, I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, RUSSIA
3
Department of Medical and Pharmaceutical Commodity Science, Saint-Petersburg State Chemical Pharmaceutical University, Saint-Petersburg, RUSSIA
4
Department of Pharmacy Management and Economics with a Course in Medical and Pharmaceutical Commodity Science, Bashkir State Medical University, Ufa, RUSSIA
Publication date: 2024-12-11
Electron J Gen Med 2024;21(6):em616
KEYWORDS
ABSTRACT
This study investigates factors influencing the cost of pharmacotherapy for primary hyperparathyroidism (PHPT) in a hospital setting to optimize therapeutic strategies and rationalize financing. The study was conducted from 2020 to 2023 and included 200 patients with PHPT from two hospitals in Moscow, Russia. The key aspects for analysis were demographic profiles, treatment methods, complications, and associated costs. The majority of patients (52.1%) were aged 60-74 years, while only 2.0% were aged 75 or older. The most frequently prescribed medications were cardiovascular drugs (33.5%) and vitamin supplements (25.1%). Colecalciferol (13.5%), bisoprolol (6.8%), and cinacalcet (4.9%) were the most common individual medications. The study revealed that the cost of conservative treatment without complications was twice that of surgical treatment. These models can aid in justifying and optimizing PHPT treatment financing in hospital settings. The findings highlight the importance of individualized treatment approaches and cost optimization strategies.
REFERENCES (43)
1.
Dandurand K, Ali DS, Khan AA. Primary hyperparathyroidism: A narrative review of diagnosis and medical management. J Clin Med. 2021;10(8):1604. https://doi.org/10.3390/jcm100... PMid:33918966 PMCid:PMC8068862.
2.
Bilezikian JP, Khan AA, Silverberg SJ, et al. International workshop on primary hyperparathyroidism. Evaluation and management of primary hyperparathyroidism: Summary statement and guidelines from the fifth international workshop. J Bone Miner Res. 2022;37(11):2293-314. https://doi.org/10.1002/jbmr.4... PMid:36245251.
3.
Kim J-K, Chai YJ, Chung JK, et al. The prevalence of primary hyperparathyroidism in Korea: A population-based analysis from patient medical records. Ann Surg Treat Res. 2018;94(5):235-9. https://doi.org/10.4174/astr.2... PMid:29732354 PMCid:PMC5931933.
4.
Makras P, Anastasilakis AD. Bone disease in primary hyperparathyroidism. Metabolism. 2018;80:57-65. https://doi.org/10.1016/j.meta... PMid:29051042.
5.
David O, Loewenthal N, Haim A, Makarov V, Hershkovitz E. Diagnosis, management, and possible prevention of hungry bone syndrome in an adolescent with primary hyperparathyroidism and vitamin D deficiency. Isr Med Assoc J. 2020;22(2):122-4.
6.
Pretorius M, Lundstam K, Heck A, et al. Mortality and morbidity in mild primary hyperparathyroidism: Results from a 10-year prospective randomized controlled trial of parathyroidectomy versus observation. Ann Intern Med. 2022;175(6):812-9. https://doi.org/10.7326/M21-44... PMid:35436153.
7.
McDow AD, Sippel RS. Should symptoms be considered an indication for parathyroidectomy in primary hyperparathyroidism? Clin Med Insights Endocrinol Diabetes. 2018;11:1179551418785135. https://doi.org/10.1177/117955... PMid:30013413 PMCid:PMC6043916.
8.
Walker MD, Silverberg SJ. Primary hyperparathyroidism. Nat Rev Endocrinol. 2018;14(2):115-25. https://doi.org/10.1038/nrendo... PMid:28885621 PMCid:PMC6037987.
9.
Mokrysheva NG, Eremkina AK, Mirnaya SS, et al. The clinical practice guidelines for primary hyperparathyroidism, short version. Probl Endokrinol (Mosk). 2021;67(4):94-124. https://doi.org/10.14341/probl... PMid:34533017 PMCid:PMC9753843.
10.
Mohan B, Abuji K, Dahiya D, Tandup C, Bhadada S, Behera A. Quality of life assessment after parathyroidectomy in symptomatic primary hyperparathyroidism using the SF-36 questionnaire. Turk J Surg. 2021;37(3):247-52. https://doi.org/10.47717/turkj... PMid:35112059 PMCid:PMC8776409.
11.
Bilezikian JP, Cusano NE, Khan AA, Liu JM, Marcocci C, Bandeira F. Primary hyperparathyroidism. Nat Rev Dis Primers. 2016;2:16033. https://doi.org/10.1038/nrdp.2... PMid:27194212 PMCid:PMC5385896.
12.
Soto-Pedre E, Newey PJ, Leese GP. Stable incidence and increasing prevalence of primary hyperparathyroidism in a population-based study in Scotland. J Clin Endocrinol Metab. 2023;108(10):e1117-24. https://doi.org/10.1210/clinem... PMid:37022975 PMCid:PMC10505547.
13.
Minisola S, Arnold A, Belaya Z, et al. Epidemiology, pathophysiology, and genetics of primary hyperparathyroidism. J Bone Miner Res. 2022;37(11):2315-29. https://doi.org/10.1002/jbmr.4... PMid:36245271 PMCid:PMC10092691.
14.
Arya AK, Kumari P, Bhadada SK, et al. Progressive rise in the prevalence of asymptomatic primary hyperparathyroidism in India: Data from PHPT registry. J Bone Miner Metab. 2021;39(2):253-9. https://doi.org/10.1007/s00774... PMid:32894354.
15.
Clarke BL. Asymptomatic primary hyperparathyroidism. Front Horm Res. 2019;51:13-22. https://doi.org/10.1159/000491... PMid:30641522.
16.
Pekkolay Z, Kilinc F, Soylu H, et al. Preoperative parenteral ibandronate for treating severe hypercalcemia associated with primary hyperparathyroidism: An effective and cheap drug. Turk J Endocrinol Metab. 2018;22(2):39-41. https://doi.org/10.25179/tjem.....
17.
Ejlsmark-Svensson H, Sikjaer T, Webb SM, Rejnmark L, Rolighed L. Health-related quality of life improves 1 year after parathyroidectomy in primary hyperparathyroidism: A prospective cohort study. Clin Endocrinol (Oxf). 2019;90(1):184-91. https://doi.org/10.1111/cen.13... PMid:30267589.
18.
Liu H, Luo K, Liao S, et al. Diagnosis and treatment of primary hyperparathyroidism with pathological fracture of the limbs: A retrospective observational study. Medicine (Baltimore). 2022;101(33):e29966. https://doi.org/10.1097/MD.000... PMid:35984170 PMCid:PMC9388023.
19.
Yeh R, Tay YD, Tabacco G, et al. Diagnostic performance of 4D CT and sestamibi SPECT/CT in localizing parathyroid adenomas in primary hyperparathyroidism. Radiology. 2019;291(2):469-76. https://doi.org/10.1148/radiol... PMid:30835187 PMCid:PMC7440755.
20.
Memeh KO, Palacios JE, Khan R, Guerrero MA. Pre-operative localization of parathyroid adenoma: Performance of 4D MRI parathyroid protocol. Endocr Pract. 2019;25(4):361-5. https://doi.org/10.4158/EP-201... PMid:30720353.
21.
Ozturk M, Polat AV, Celenk C, Elmali M, Kir S, Polat C. The diagnostic value of 4D MRI at 3T for the localization of parathyroid adenomas. Eur J Radiol. 2019;112:207-13. https://doi.org/10.1016/j.ejra... PMid:30777212.
22.
Caldwell M, Laux J, Clark M, Kim L, Rubin J. Persistently elevated PTH after parathyroidectomy at one year: Experience in a tertiary referral center. J Clin Endocrinol Metab. 2019;104(10):4473-80. https://doi.org/10.1210/jc.201... PMid:31188435 PMCid:PMC6736213.
23.
Livschitz J, Yen TWF, Evans DB, Wang TS, Dream S. Long-term quality of life after parathyroidectomy for primary hyperparathyroidism: A systematic review. JAMA Surg. 2022. https://doi.org/10.1001/jamasu... PMid:36103163.
24.
Belozeroff V, Cooper K, Hess G, Chang CL. Healthcare use and costs before and after parathyroidectomy in patients on dialysis. BMC Health Serv Res. 2013;13:248. https://doi.org/10.1186/1472-6... PMid:23819622 PMCid:PMC3750363.
25.
Joy MS, Karagiannis PC, Peyerl FW. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J Manag Care Pharm. 2007;13(5): 397-411. https://doi.org/10.18553/jmcp.... PMid:17605511 PMCid:PMC10437388.
26.
Lorenz FJ, Beauchamp-Perez F, Manni A, Chung T, Goldenberg D, Goyal N. Analysis of time to diagnosis and outcomes among adults with primary hyperparathyroidism. JAMA Netw Open. 2022;5(12):e2248332. https://doi.org/10.1001/jamane... PMid:36574247 PMCid:PMC9857508.
27.
van Mossel S, Saing S, Appelman-Dijkstra N, et al. Cost-effectiveness of one-stop-shop [18F]fluorocholine PET/CT to localise parathyroid adenomas in patients suffering from primary hyperparathyroidism. Eur J Nucl Med Mol Imaging. 2024;51(12):3585-95. https://doi.org/10.1007/s00259... PMid:38837058 PMCid:PMC11457719.
28.
Yap A, Hope TA, Graves CE, et al. A cost-utility analysis of 18F-fluorocholine-positron emission tomography imaging for localizing primary hyperparathyroidism in the United States. Surgery. 2022;171(1):55-62. https://doi.org/10.1016/j.surg... PMid:34340823.
29.
Frank E, Watson W, Fujimoto S, De Andrade Filho P, Inman J, Simental A. Surgery versus imaging in non-localizing primary hyperparathyroidism: A cost-effectiveness model. Laryngoscope. 2020;130(12):E963-9. https://doi.org/10.1002/lary.2....
30.
Lukyanenko N, Spaska A, Lenha E, Marazha I. Frequency of polymorphic loci of GSTM1 and GSTT1 modifier genes in the genotype of children with pyelonephritis and congenital urinary malformations. Pol Ann Med. 2023;30(1):9-14. https://doi.org/10.29089/paom/....
31.
Aringazina R, Kurmanalina G, Kurmanalin B, Degtyarevskaya T. Role of vitamin D in prevention of metabolic syndrome and cardiovascular diseases. Bangladesh J Med Sci. 2021;20(2):431-8. https://doi.org/10.3329/bjms.v....
32.
Reid L, Muthukrishnan B, Patel D, et al. Presentation, diagnostic assessment and surgical outcomes in primary hyperparathyroidism: A single centre’s experience. Endocr Connect. 2018;7(10):1105-15. https://doi.org/10.1530/EC-18-... PMid:30139819 PMCid:PMC6198194.
33.
Pretorius M, Lundstam K, Hellström M, et al. Effects of parathyroidectomy on quality of life: 10 years of data from a prospective randomized controlled trial on primary hyperparathyroidism (the SIPH-study). J Bone Miner Res. 2021;36(1):3-11. https://doi.org/10.1002/jbmr.4... PMid:33125769.
34.
Battistella E, Pomba L, Toniato R, et al. Evolution of the diagnosis and treatment of primary hyperparathyroidism. J Clin Med. 2023;12(5):2057. https://doi.org/10.3390/jcm120... PMid:36902844 PMCid:PMC10004239.
35.
Ye Z, Silverberg SJ, Sreekanta A, et al. The afficacacy and safety of medical and surgical therapy in patients with primary hyperparathyroidism: A systemetic review and meta-analysis of randomized controlled trials. J Bone Miner Res. 2022;37(11):2351-72. https://doi.org/10.1002/jbmr.4... PMid:36053960.
36.
Bell D, Hale J, Go C, et al. A single-centre retrospective analysis of cinacalcet therapy in primary hyperparathyroidism. Endocr Connect. 2021;10(11):1435-44. https://doi.org/10.1530/EC-21-... PMid:34647901 PMCid:PMC8630765.
37.
Yamamoto K, Nakano Y, Tokumasu K, et al. Relationship between patients’ characteristics and efficacy of calcimimetics for primary hyperparathyroidism in the elderly. Clin Case Rep. 2022;10(4):e05713. https://doi.org/10.1002/ccr3.5... PMid:35425612 PMCid:PMC8991766.
38.
Iwamoto N, Sato N, Nishida M, et al. Total parathyroidectomy improves survival of hemodialysis patients with secondary hyperparathyroidism. J Nephrol. 2012;25(5):755-63. https://doi.org/10.5301/jn.500... PMid:22135031.
39.
Darbà J, Marsà A. Epidemiology and management of parathyroid gland disorders in Spain over 15 years: A retrospective multicentre analysis. PLoS One. 2020;15(3):e0230130. https://doi.org/10.1371/journa... PMid:32155210 PMCid:PMC7064228.
40.
Zhang Z, Cai L, Wu H, et al. Paricalcitol versus calcitriol + cinacalcet for the treatment of secondary hyperparathyroidism in chronic kidney disease in China: A cost-effectiveness analysis. Front Public Health. 2021;9:712027. https://doi.org/10.3389/fpubh.... PMid:34368073 PMCid:PMC8333861.
41.
Lala M. Management of primary hyperparathyroidism. Indian J Surg Oncol. 2022;13(1):143-51. https://doi.org/10.1007/s13193... PMid:35462664 PMCid:PMC8986895.
42.
Iwata AJ, Wertz AS, Alluri S, Singer MC. A faster parathyroidectomy: Techniques to shorten non-surgical operating room time. Am J Otolaryngol. 2019;40(6):102292. https://doi.org/10.1016/j.amjo... PMid:31537429.
43.
Slattery L, Hunt JP. Contemporary management of primary hyperparathyroidism. Surg Clin North Am. 2022;102(2):251-65. https://doi.org/10.1016/j.suc.... PMid:35344696.
| eISSN: | 2516-3507 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
